PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ADMA vs. ARQT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ADMA and ARQT is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

ADMA vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%400.00%500.00%JulyAugustSeptemberOctoberNovemberDecember
339.39%
-31.24%
ADMA
ARQT

Key characteristics

Sharpe Ratio

ADMA:

4.97

ARQT:

5.57

Sortino Ratio

ADMA:

5.30

ARQT:

4.55

Omega Ratio

ADMA:

1.72

ARQT:

1.54

Calmar Ratio

ADMA:

4.86

ARQT:

5.15

Martin Ratio

ADMA:

39.90

ARQT:

22.35

Ulcer Index

ADMA:

8.16%

ARQT:

21.42%

Daily Std Dev

ADMA:

65.42%

ARQT:

85.91%

Max Drawdown

ADMA:

-91.28%

ARQT:

-95.02%

Current Drawdown

ADMA:

-23.08%

ARQT:

-59.46%

Fundamentals

Market Cap

ADMA:

$4.40B

ARQT:

$1.74B

EPS

ADMA:

$0.27

ARQT:

-$1.67

Total Revenue (TTM)

ADMA:

$382.81M

ARQT:

$138.71M

Gross Profit (TTM)

ADMA:

$186.78M

ARQT:

$124.04M

EBITDA (TTM)

ADMA:

$98.48M

ARQT:

-$167.33M

Returns By Period

In the year-to-date period, ADMA achieves a 284.96% return, which is significantly lower than ARQT's 364.09% return.


ADMA

YTD

284.96%

1M

-18.58%

6M

58.18%

1Y

321.31%

5Y*

32.75%

10Y*

4.61%

ARQT

YTD

364.09%

1M

47.25%

6M

76.56%

1Y

476.54%

5Y*

N/A

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ADMA vs. ARQT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ADMA, currently valued at 4.97, compared to the broader market-4.00-2.000.002.004.975.57
The chart of Sortino ratio for ADMA, currently valued at 5.30, compared to the broader market-4.00-2.000.002.004.005.304.55
The chart of Omega ratio for ADMA, currently valued at 1.72, compared to the broader market0.501.001.502.001.721.54
The chart of Calmar ratio for ADMA, currently valued at 13.22, compared to the broader market0.002.004.006.0013.225.15
The chart of Martin ratio for ADMA, currently valued at 39.90, compared to the broader market-5.000.005.0010.0015.0020.0025.0039.9022.35
ADMA
ARQT

The current ADMA Sharpe Ratio is 4.97, which is comparable to the ARQT Sharpe Ratio of 5.57. The chart below compares the historical Sharpe Ratios of ADMA and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00JulyAugustSeptemberOctoberNovemberDecember
4.97
5.57
ADMA
ARQT

Dividends

ADMA vs. ARQT - Dividend Comparison

Neither ADMA nor ARQT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ADMA vs. ARQT - Drawdown Comparison

The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for ADMA and ARQT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-23.08%
-59.46%
ADMA
ARQT

Volatility

ADMA vs. ARQT - Volatility Comparison

The current volatility for ADMA Biologics, Inc. (ADMA) is 13.24%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 23.51%. This indicates that ADMA experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
13.24%
23.51%
ADMA
ARQT

Financials

ADMA vs. ARQT - Financials Comparison

This section allows you to compare key financial metrics between ADMA Biologics, Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab